Leucine Rich Repeat Kinase 2 (LRRK2) is the most commonly mutated gene in familial Parkinson's disease. LRRK2 is proposed to function in membrane trafficking and co-localizes with microtubules. We report the 3.5Å structure of the catalytic half of LRRK2, and an atomic model of microtubule-associated LRRK2 built using a reported 14Å cryo-electron tomography in situ structure. We propose that the conformation of LRRK2's kinase domain regulates its microtubule interaction, with a closed conformation favoring binding. We show that the catalytic half of LRRK2 is sufficient for microtubule binding and blocks the motility of the microtubule-based motors kinesin and dynein in vitro. Kinase inhibitors that stabilize an open conformation relieve this interference and reduce LRRK2 filament formation in cells, while those that stabilize a closed conformation do not. Our findings suggest that LRRK2 is a roadblock for microtubule-based motors and have implications for the design of therapeutic LRRK2 kinase inhibitors.
Introduction
Mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the most common cause of familial Parkinson's Disease (PD) 1 . LRRK2 is also linked to the idiopathic form of PD: mutations in LRRK2 are a genetic risk factor 1 and increased LRRK2 kinase activity is linked to disease 2 . A growing body of evidence suggests that mutations in LRRK2 are also risk factors for Crohn's Disease and leprosy [3] [4] [5] . Like many other PD-causing genes, LRRK2 is implicated in membrane trafficking 6 . Mutant LRRK2 causes defects in the trafficking of endosomes, lysosomes, autophagosomes, and mitochondria 6, 7 . Furthermore, Rab GTPases, central regulators of membrane trafficking, are physiological substrates of LRRK2 8, 9 . In cells, all five major PD-causing mutations increase the phosphorylation of LRRK2's Rab substrates 8, 9 . Long-distance transport of Rab-marked membranes occurs along microtubules and is driven by the microtubule-based motors dynein and kinesin 10, 11 . LRRK2 function and/or pathology has also been linked to microtubules as LRRK2 partially co-localizes with microtubules in cells 12 and four of the five major PD-causing mutations ( Fig. 1a) 1 enhance microtubule association of LRRK2 13 .
LRRK2 is a large (288 kDa) multi-domain protein. Its aminoterminal half is comprised of repetitive protein interaction motifs (Armadillo, Ankyrin, and Leucine-Rich Repeats) and its carboxyterminal catalytic half contains a Ras-like GTPase (Ras-of-Complex, or RoC domain), a kinase domain, and two other domains (C-terminal Of Roc, or COR, and WD40) ( Fig. 1a ). Despite LRRK2's fundamental importance for understanding and treating PD, there is limited structural information on LRRK2. While structures are available for bacterial homologs of the LRR, RoC and COR domains 14, 15 , and a D. discoideum homolog of the kinase domain 16 , the only two high-resolution structures available for the human protein are for its RoC 17 and WD40 domains 18 and no larger structures have been reported. Structures of the full-length protein obtained using negative stain 19 and cryo-electron microscopy (Cryo-EM) 20 have been published, but their resolutions were limited (22Å and 16Å, respectively). A recent reconstruction of LRRK2 bound to microtubules in cells using cryo-electron tomography (Cryo-ET) and sub-tomogram averaging led to a 14Å structure and proposed model of the catalytic half of LRRK2 21 . Here, we set out to determine a highresolution structure of LRRK2's catalytic half using cryo-EM, as well as to understand how it interacts with microtubules and how this impacts the movement of microtubule-based motors.
We determined a 3.5Å structure of LRRK2 RCKW in the presence of GDP using cryo-EM (Fig. 1b, c and Extended Data Fig. 2 ). On our grids, we observed a mixture of monomers, dimers and head-to-tail trimers and we used the trimer to solve the structure ( Fig. 1b and Extended Data Fig. 2b ). This trimer species was critical for reaching high resolution, but it is likely specific to the EM grid preparation as LRRK2 RCKW is predominantly monomeric, with a smaller percentage of dimers, in solution (Extended Data Fig. 3 ). The RoC and COR-A domains were flexible in our structure, yielding significantly lower resolutions than the rest of the protein as a result of the symmetry imposed on the trimer (Fig. 1b, c) . In order to improve the density of this part of the map, we used signal subtraction to generate LRRK2 RCKW trimers containing only one of the three RoC and COR-A domains and subjected those to 3D classification and refinement focused on the monomer containing RoC and COR-A. This resulted in a 3.8Å structure with improved local resolution for RoC and COR-A ( Fig. 1d , e, Extended Figure 1 | Cryo-EM structure of LRRK2 RCKW . a, Schematic of the construct used in this study, with amino acid numbers of the beginning and end indicated. The N-terminal half of LRRK2, absent from our construct, is shown in dim colors. The same color-coding of domains is used throughout the paper. The five major familial Parkinson's Disease mutations and a Crohn's Disease-linked mutation are indicated below the diagram. b, 3.5Å map of the LRRK2 RCKW trimer, with one monomer highlighted using the colors shown in (a). c, Local resolution of the map shown in (b). d, Density for a LRRK2 RCKW monomer obtained after processing data where the RoC and COR-A domains were signal-subtracted from two of the monomers in each trimer (see Methods and Extended Data Fig. 2 for details). e, Local resolution for the monomer in (d), showing the improvements in the RoC and COR-A domains. f, Ribbon diagram of the atomic model of LRRK2 RCKW . g, An 8.1Å cryo-EM map of monomeric LRRK2 RCKW with the atomic model built from the trimer docked in. h, Close up of the area highlighted by the dashed box in (g). i, Each LRRK2 RCKW domain is highlighted in color in the context of an otherwise grey ribbon representation of the full structure. j, k, Location of the Parkinson's and Crohn's Disease mutations listed in (a). l, Interface between the C-terminal helix and the kinase domain in LRRK2 RCKW . m, details of the electrostatic and hydrophobic interactions found at that interface, with the residues involved indicated.
Data Fig. 2f -i). We used a combination of Rosetta 22 and manual building in coot 23 to generate the final model. The RoC and COR-A domains were built using the signal subtracted maps, and then combined with the COR-B, kinase and WD40 domains, which were built using the original higher resolution trimer map ( Fig. 1f and Extended Data Video 1). Importantly, the atomic model of LRRK2 RCKW we obtained from the trimers fits well into an 8.1Å reconstruction of a LRRK2 RCKW monomer (Fig. 1g, h) , indicating that formation of the trimer does not cause major structural changes in the protein.
LRRK2 RCKW adopts an overall J-shaped structure, with the WD40, kinase and COR-B domains arranged along one axis, and COR-A and RoC turning around back towards the kinase, bringing COR-A, and therefore the tightly associated RoC domain, which has GDP bound, in close proximity to the kinase's C-lobe ( Fig. 1f , i and Extended Data Video 1). This arrangement likely underpins the reported crosstalk between LRRK2's kinase and GTPase 24, 25 (reviewed in 26 ). Part of the FERM domain in the FAK-FERM complex approaches the FAK C-lobe in a similar way 27 (Extended Data Fig. 4a, b ). The RoC, COR-A and COR-B domains are arranged as previously seen in crystal structures of the COR 14 , RoC-COR 14, 28 , and LRR-RoC-COR 15 fragments of bacterial homologs of LRRK2. The N-lobe of the LRRK2 RCKW kinase domain, in particular its aC helix, forms an extensive interaction with the COR-B domain, with COR-B occupying a location reminiscent of that of Cyclin A in CDK2-Cyclin A 29 (Extended Data Fig. 4a , c).
The kinase in LRRK2 RCKW is in an open, inactive conformation. Its activation loop is disordered beyond G2019, the location of one of the major familial PD mutations (G2019S) (Fig. 1j , k and Extended Data Video 2). Thus, I2020, the location of the other familial PD mutation found in the activation loop (I2020T), is disordered in our structure (Fig. 1j , k and Extended Data Video 2). R1441 and Y1699 are the sites of three other familial PD mutations and are located at the RoC-COR-B interface (Fig. 1j , k and Extended Data Video 2). Y2018 of the DYG motif (DFG motif in other kinases) is within hydrogen-bonding distance of the backbone carbonyl of I1933 in the N-lobe (Extended Data Fig. 4j , k). Given that a Y2018F mutation leads to hyperactivation of LRRK2's kinase 30 , it is possible that a Y2018-I1933 hydrogen bond keeps the activation loop in an inactive conformation.
A unique feature of LRRK2 is a 28-amino acid a-helix located at its extreme C-terminus, following the WD40 domain ( Fig. 1i , l, m and Extended Data Video 3). This helix extends along the entire kinase domain, interacting with both its C-and N-lobes ( Fig. 1l , m and Extended Data Video 3). Deletion of this helix resulted in an insoluble protein (Extended Data Fig.1 ). While a number of other kinases have alpha helices in the same general location as LRRK2's C-terminal helix, none of those interactions are as extensive as that observed in LRRK2 (Extended Data Fig. 4d -i). A residue near its end (T2524) is a known phosphorylation site for LRRK2 31 . Given the close proximity between T2524 and the N-lobe of the kinase domain, as well as the adjacent COR-B domain, we hypothesize that phosphorylation of this residue may play a role in regulating the kinase. Since the last two residues of the Cterminal helix are disordered in our structure, as is a neighboring loop in COR-B, it is possible that conditions exist where these regions become ordered and turn the C-terminal helix into an anchoring element that connects COR-B, the kinase and the WD40 domain.
Although our construct lacks the N-terminal half of full-length LRRK2, we were able to model the Leucine-Rich Repeats (LRR) by using a recent crystal structure of the LRR, RoC, and COR domains of C. tepidum's Roco protein, a bacterial homolog of LRRK2 15 (Extended Data Fig. 5a-e ). Aligning the RoC and COR domains of this structure to those of LRRK2 RCKW resulted in a good fit for the LRR, which in the model wraps around the N-lobe of the kinase and comes in close proximity of its C-lobe as it connects to the RoC domain (Extended Data Fig. 5a-e ). This model places the known S1292 autophosphorylation site in the LRR in close proximity to the kinase's active site, and the Crohn's disease-related residue N2081, located in the kinase's C-lobe adjacent to the LRR (Extended Data Fig. 5f ), suggesting the functional relevance of this potential interface.
An atomic model of microtubule-bound LRRK2 filaments
Recently, a 14Å structure of microtubule-associated filaments of fulllength LRRK2 (carrying the filament-promoting I2020T mutation 13 ) was reported using in situ cryo-ET and sub-tomogram averaging 21 (Fig. 2a ). The LRRK2 filaments formed on microtubules were right-handed 21 . The fact that microtubules are left-handed, combined with the absence of Fig. 2j , k is shown here in grey, with either a WD40-mediated (a), or COR-mediated (c) LRRK2 RCKW dimer highlighted with domain colors. The corresponding molecular models are shown next to the cartoons (b, d). e, f, Cryo-EM reconstructions of LRRK2 RCKW dimers obtained in the absence of inhibitor ("Apo"), or in the presence of MLi-2. The molecular models (left) are the same ones shown in (b, d) for the WD40-mediated (e) and COR-mediated (f) LRRK2 RCKW dimers. The models are shown in an orientation that matches the cryo-EM maps shown in the first column. For each reconstruction, two orientations of the map are shown: down the two-fold axis at the dimerization interface (left), and perpendicular to it (right). For each species, the top row shows the cryo-EM map and the bottom row a transparent version of the map with a model docked in. The models docked into the maps obtained in the presence of MLi-2 are those derived from building the filaments ( Fig. 2g -i). Those docked into the maps obtained in the absence of inhibitor were built with the LRRK2 RCKW structure (i.e. with an open kinase) but maintaining the interfaces identified in the filaments. Both types of dimers were also observed in the presence of Ponatinib but the preferred orientation of the sample prevented us from obtaining a 3D reconstruction; Extended Data Fig. 10 shows 2D class averages instead. g, We built molecular models of the WD40-mediated and COR-mediated dimers of LRRK2 RCKW obtained in the presence of MLi-2 (e, f) by fitting the two halves of LRRK2 RCKW split at the junction between the N-and C-lobes of the kinase (see Extended Data Fig. 11 ). We then aligned, in alternating order, copies of these dimers. This panel shows the resulting right-handed helix. h, i, The helix has dimensions compatible with the diameter of a 12-protofilament microtubule (EMD-5192) 53 , which was the species used to obtain the tomographic reconstruction shown in Fig. 2a 21 , and has its RoC domains pointing towards the microtubule surface. strong density connecting the LRRK2 filament to the microtubule surface 21 raised the question of whether LRRK2's interaction with microtubules is direct or is mediated by other microtubule-associated proteins. To address this, we combined purified microtubules with purified LRRK2 RCKW and observed them by cryo-EM. The resulting helical microtubule decoration ( Fig. 2b ) suggests that the interaction between LRRK2 and microtubules is direct and that the catalytic Cterminal half of LRRK2 is sufficient for the formation of microtubuleassociated filaments.
Previously, integrative modeling was used to build a model into the in situ structure of microtubule-associated LRRK2 21 . This modeling indicated that the observed density was comprised of the RoC, COR, Kinase and WD40 domains and gave orientation ensembles for each domain 21 that were in good agreement with the high-resolution structure of LRRK2 RCKW presented here. However, given the uncertainties in the domain orientations intrinsic to the integrative modeling approach, we set out to build an atomic model of the microtubule-bound LRRK2 filaments by combining our 3.5Å structure of LRRK2 RCKW with the 14Å in situ structure of microtubule-associated LRRK2. To guide model building, we took advantage of the characteristic shape of the WD40 domains, which are a prominent feature of the in situ structure ( Fig. 2a and Extended Data Fig. 6a -c) and that a crystal structure of a WD40 dimer from LRRK2 was recently reported 18 . We first replaced the WD40 domains in the crystal structure with those from our LRRK2 RCKW structure (there are small differences between them) (Extended Data Fig.  6a ) and then docked this WD40 dimer into the sub-tomogram average density (Extended Data Fig. 6b ). Next, we aligned the LRRK2 RCKW structure to it, thus imposing the WD40 dimer interface from the crystal structure on our model (Extended Data Fig. 6d, e ). This initial model revealed that the LRRK2 RCKW structure is sufficient to account for the density seen in the in situ structure (Fig. 2a, c) , in agreement with our ability to reconstitute microtubule-associated LRRK2 RCKW filaments in vitro (Fig. 2b) , and with the earlier integrative modeling 21 .
Although the LRRK2 RCKW structure fits the overall shape of the sub-tomogram average, we noticed significant clashes at the filament interface formed by the COR domains ( Fig. 2d, e ). Since the kinase in our LRRK2 RCKW structure is in an open conformation ( Fig. 2c ), we wondered whether filament formation might require LRRK2's kinase to be in a closed conformation. We modeled a kinase-closed LRRK2 RCKW by running structural searches (DALI server) with either the N-or Clobes of LRRK2 RCKW 's kinase and looking for a kinase in a closed conformation whose N-and C-lobes best matched those of LRRK2 RCKW . The top candidate was Interleukin-2 inducible T-cell kinase (ITK) (PDB: 3QGY). We aligned ITK to LRRK2 RCKW using the C-lobes of the two kinases, and then aligned the N-lobe of LRRK2 RCKW 's kinase to that of ITK, moving RoC, COR-A and COR-B as a rigid body along with the Table 1 for all source data and replicate information.
kinase's N-lobe ( Fig. 2f and Extended Data Fig. 6f-j) . We then repeated the docking into the in situ structure, this time using the model of kinaseclosed LRRK2 RCKW . In addition to improving the fit visually (Fig. 2g, h) , using the kinase-closed LRRK2 RCKW model resolved more than 80% of the backbone clashes we had observed with our kinase-open LRRK2 RCKW structure (Fig. 2i) . A closed conformation for the kinase had already been proposed by the earlier integrative modeling 21 . Given this data, we hypothesize that the conformation of LRRK2, as driven by the kinase, controls its ability to associate with microtubules, with a closed kinase promoting oligomerization, which increases binding, and an open (inactive) one disfavoring it (Fig. 2j, k) .
The LRRK2 filaments in our kinase-closed model are formed by two types of homotypic interactions, each resulting in a two-fold axis of symmetry perpendicular to the microtubule axis: one is mediated by the WD40 domain, and the other by the COR-A and COR-B domains ( Fig. 3a-d) . Similar interfaces were reported based on integrative modeling performed with the 14Å LRRK2 structure obtained by cryo-ET 21 . We wondered whether these interfaces were specific to the Table 1 for all source data and replicate information. g, Schematic representation of our hypothesis that the conformation of LRRK2's kinase controls its association with microtubules. LRRK2 (represented here by LRRK2 RCKW ) can have its kinase in either an open or closed conformation. The different species we observed (monomers and both COR-and WD40-mediated dimers) are represented in the rounded rectangles, but only monomers are shown on the microtubule for simplicity. Our model proposes that only the kinase-closed form of LRRK2 is compatible with the formation of microtubule-associated filaments. The figure shows a single turn of a LRRK2 filament to emphasize that we propose that shorter species will be the relevant ones under physiological conditions. The two interfaces that mediate filament formation, which are the same ones observed in the dimers, are indicated. microtubule-associated form of LRRK2. Additional structures we obtained from our cryo-EM data showed this was not the case; in addition to the trimers we used to obtain the 3.5Å structure of LRRK2 RCKW , grids prepared in the absence of microtubules also contained dimers that were mediated by the same two interfaces seen in the filaments (Fig. 3e, f and Extended Data Figs. 7-10). We observed these dimers under different conditions, both in the presence and absence of kinase inhibitors (Fig. 3e , f and Extended Data Fig. 10 ). All of our cryo-EM maps of dimers fit well the molecular models of dimers derived from the filaments, suggesting that the same interfaces observed off microtubules are involved in the formation of the microtubule-associated filaments.
Separately, we docked LRRK2 RCKW , split in half at the junction between the N-and C-lobes of the kinase, into the cryo-EM map of a WD40-mediated dimer obtained in the presence of MLi-2 (Extended Data Fig. 11a-c) . We docked the resulting closed-kinase model of LRRK2 RCKW (Extended Data Fig. 11e ) into the cryo-EM maps of WD40and COR-mediated dimers obtained in the presence of MLi-2 to generate molecular models of these dimers (Extended Data Fig. 11c, d-g) . Finally, we aligned these models, in alternating order, to build a polymer in silico. The resulting structure was a right-handed helix with the same general geometric properties seen in the cellular LRRK2 filaments, indicating that those properties are largely encoded in the structure of LRRK2 RCKW itself (Fig. 3g-i and Extended Data Fig. 11g, h) . Docking the same two halves of LRRK2 RCKW into the cryo-EM map of a monomer obtained in the absence of inhibitors led to a structure very similar to that obtained from the trimers, further confirming that formation of the trimer did not alter the conformation of LRRK2 RCKW (Extended Data Fig. 11a, b, d, e ).
These data, along with the apparent lack of any residue-specific interactions between LRRK2 and the microtubule, suggest that the microtubule may be providing a surface for LRRK2 to oligomerize using interfaces that exist in solution. Consistent with this idea, the surface charge of the microtubule facing the LRRK2 RCKW filament is acidic, while there are a number of basic patches on the LRRK2 RCKW filament facing the microtubule (Extended Data Fig. 12) . The unstructured Cterminal tails of aand b-tubulin, which were not included in the surface charge calculations, are also acidic. Finally, the interface in the CORmediated dimer we observed for LRRK2 RCKW differs from that reported for the homologous Roco protein from C. tepidum 14, 15 (Extended Data Fig. 13 ). While the GTPase domains interact directly in the dimer of the bacterial protein 15 , they are not involved in the dimerization interface of LRRK2 (Extended Data Fig. 13d, e ).
LRRK2 RCKW inhibits kinesin and dynein motility in vitro
To test our hypothesis that the conformation of LRRK2's kinase domain regulates its interaction with microtubules, we needed a sensitive assay to measure the association of LRRK2 RCKW with microtubules and a means to control the conformation of its kinase. Microtubule association was monitored by measuring the effect of LRRK2 RCKW on the movement of microtubule-based motors. We used a truncated dimeric human kinesin-1, Kif5B ("kinesin" here) 32 , which moves towards the plus ends of microtubules, and activated human cytoplasmic dynein-1/ dynactin/ ninein-like complexes ("dynein" here) 33 , which move in the opposite direction. Using single-molecule in vitro motility assays (Fig. 4a ) we found that low nanomolar concentrations of LRRK2 RCKW inhibited both kinesin and dynein movement, with near complete inhibition achieved at 25 nM LRRK2 RCKW (Fig. 4b-e ). We hypothesized that LRRK2 RCKW was acting as a roadblock for the motors. In agreement with this hypothesis, the run length of kinesin was reduced (Fig. 4f) , while its velocity remained relatively constant (Fig. 4g ). Activated cytoplasmic dynein-1 complexes also showed a significant reduction in run length in the presence of LRRK2 RCKW (Fig. 4h) . Thus, LRRK2 RCKW robustly blocked the motility of both kinesin and dynein motors in vitro.
Ponatinib and GZD-824 rescue motor inhibition by LRRK2 RCKW in vitro
Our hypothesis predicts that the closed conformation of LRRK2's kinase domain will favor microtubule binding. Conversely, it predicts that conditions that stabilize the kinase in an open conformation will lead to decreased microtubule binding of LRRK2 RCKW , resulting in relief of LRRK2 RCKW -dependent inhibition of kinesin and dynein motility. To test these predictions, we searched for a Type 2 kinase inhibitor that binds tightly to LRRK2 with structural evidence that it stabilizes an open kinase conformation. We selected Ponatinib as our initial candidate inhibitor as it has a reported Ki for LRRK2 of 31 nM 34 , and crystal structures show it bound to RIPK2 35 and IRAK4 in open conformations (Extended Data Fig. 14) . We confirmed that Ponatinib also inhibited LRRK2 RCKW by monitoring phosphorylation of the known LRRK2 substrate, Rab8a 8 in vitro (Extended Data Fig. 15a ).
As our hypothesis predicted, Ponatinib rescued kinesin motility in a dose-dependent manner at concentrations of LRRK2 RCKW (25 nM) that had resulted in almost complete inhibition of the motors (Fig. 5a , Extended data Fig. 15b-e ). We observed similar effects with GZD-824, a chemically-related Type 2 kinase inhibitor 36 (Fig. 5a and Extended Data Fig. 15d, e ). Our hypothesis also predicted that kinase inhibitors that stabilize the closed form of the kinase should be unable to rescue the motors and may even enhance the inhibitory effect of LRRK2 RCKW by increasing its interaction with microtubules. Indeed, the LRRK2-specific Type 1 inhibitors MLi-2 37,38 and LRRK2-IN-1 39 , which are known 40 or expected 37 to stabilize a closed conformation of the kinase, further enhanced the inhibitory activity of LRRK2 RCKW on kinesin motility (Fig.  5a) . As was the case with Ponatinib, GZD-824, MLi-2 and LRRK2-IN-1 all inhibited phosphorylation of Rab8a by LRRK2 RCKW (Extended Data Fig. 15a ). Similar to kinesin, dynein motility was rescued by Ponatinib and GZD-824, but not MLi-2 or LRRK2-IN-1 ( Fig. 5b and Extended Data Fig. 15d, f) . These data suggest that the effects of LRRK2 kinase inhibitors on microtubule-based motility should be taken into account when designing LRRK2-targeted PD therapeutics.
GZD-824 reduces filament formation in cells
In cells, LRRK2 forms filaments that colocalize with a subset of microtubules and are sensitive to the microtubule depolymerizing drug nocodazole 13 . This association is enhanced by the PD-linked mutations R1441C, R1441G, Y1699C and I2020T 13, 41 and by Type 1 kinase inhibitors 39, 42 . We tested our kinase conformation hypothesis in 293T cells by determining if Type 1 and Type 2 kinase inhibitors had opposite effects on the formation of cellular microtubule-associated LRRK2 filaments. Consistent with previous findings, the Type 1 inhibitor MLi-2 enhanced LRRK2's-microtubule association (Fig. 5c, d ), suggesting that the closed conformation of the kinase favors binding to microtubules in cells. In contrast, we found that the Type 2 inhibitor GZD-824 reduced the filament-forming ability of overexpressed LRRK2 (carrying the mutation I2020T; Fig. 5e, f) . This reduction in LRRK2 filament formation was not due to changes in LRRK2 protein expression levels (Extended Data Fig. 16a, b) or the overall architecture of the microtubule cytoskeleton (Extended Data Fig. 16c ).
Discussion
Here we reported the 3.5Å structure of the catalytic half of LRRK2 (LRRK2 RCKW ), where most major PD-linked mutations are located. Our model represents the first structure of a large portion of human LRRK2 with sufficient resolution to yield molecular information about LRRK2's activity and its regulation. LRRK2 RCKW is J-shaped, which brings its GTPase (RoC domain) and kinase in close proximity despite their separation along the linear sequence of LRRK2. The direct contact we observe between the C-lobe of the kinase and COR-A, which is closely associated with the GTPase, provides a structural context for the crosstalk between these two catalytic domains (reviewed in 26 ). Our cryo-EM structure, obtained in the absence of kinase inhibitors, shows the kinase in an open (inactive) conformation. A unique feature of the structure is a long alpha helix located at the C-terminus of LRRK2, following the WD40 domain. Running along the long axis of the kinase domain, this helix has multiple interactions with both its N-and C-lobes. Given these interactions, and the presence of a known phosphorylation site near its end (T2524) 31 , it is likely that this helix plays an important role in regulating LRRK2's kinase activity.
Our ability to generate microtubule-associated LRRK2 RCKW filaments using purified components demonstrates that these filaments can form in the absence of other proteins and that the C-terminal half of LRRK2 is sufficient for their assembly. This is also in agreement with the observation that our LRRK2 RCKW structure accounts for the filament density observed in a recent 14Å structure of LRRK2-microtubule associated filaments in cells obtained by cryo-ET 21 .
We used the high-resolution structure of LRRK2 RCKW , in combination with the 14Å in situ structure 21 , to build an atomic model of the microtubule-associated LRRK2 filaments. Docking of our LRRK2 RCKW structure, with its open kinase domain, into the microtubule-associated in situ structure led to significant steric clashes. These clashes were largely resolved by modeling LRRK2's kinase in a closed conformation, leading us to hypothesize that the conformation of LRRK2's kinase controls its association with microtubules, with a closed conformation favoring its oligomerization on microtubules (Fig. 5g ). In our model of microtubule-associated LRRK2 RCKW filaments, the filaments form through head-head and tail-tail interactions involving either the COR or WD40 domains of LRRK2. Formation of these interfaces does not require LRRK2 to interact with microtubules, as we obtained lower resolution cryo-EM structures of both types of LRRK2 RCKW dimers in the absence of microtubules. In addition, aligning atomic models of these dimers in silico resulted in a right-handed filament with similar geometric properties to the LRRK2 filaments observed in cells 21 . Thus, the ability of LRRK2 to form filaments is a property inherent to LRRK2, and specifically the RCKW domains. Since LRRK2 RCKW exists both as a monomer and dimer in solution, it remains to be determined what the minimal filament-forming unit is. We propose that the surface charge complementarity between the microtubule and LRRK2, as well as the size and shape of the microtubule stimulates the formation of LRRK2 filaments.
We tested the model that the conformation of LRRK2's kinase regulates microtubule association both in vitro and in cells using kinase inhibitors that are known or expected to stabilize either the open (Type 2) or closed (Type 1) conformations of the kinase. In support of our model, Type 2 inhibitors relieved the LRRK2 RCKW -dependent inhibition of the microtubule-based motors kinesin and dynein and reduced LRRK2 filament formation in cells, while Type 1 inhibitors failed to rescue the motors and enhanced filament formation in cells. In contrast to our structural studies, which used high concentrations of LRRK2 RCKW (cryo-EM) or overexpressed LRRK2 in cells (cryo-ET), our single-molecule motility assays showed that low nanomolar concentrations of LRRK2 RCKW negatively impact the microtubule-based motility of both kinesin and dynein in vitro. At these low concentrations it is likely that LRRK2 would not form the long, highly ordered filaments and microtubule bundles observed in cells overexpressing the protein; instead, we hypothesize that at endogenous expression levels in cells LRRK2 forms short stretches of filaments on microtubules.
Our data showing that increasing concentrations of LRRK2 RCKW dramatically shorten the distance kinesin moves (run length), without affecting its velocity suggest that LRRK2 acts as a roadblock. Other microtubule-associated proteins (MAPs), such as MAP2 and Tau, also inhibit kinesin motors 43 (bioRxiv 10.1101/731604). In contrast to kinesin, dynein is largely unaffected by MAP2 and Tau 43 (bioRxiv 10.1101/731604), likely due to its ability to sidestep to adjacent protofilaments [44] [45] [46] . LRRK2's unusual ability to inhibit dynein motility may be a consequence of its forming oligomers that block dynein's sidestepping.
What is the physiological role of non-pathogenic microtubuleassociated LRRK2? Our data show that low nanomolar concentrations of LRRK2 act as a roadblock for microtubule-based motors. Dynein and kinesin have been shown to bind directly or indirectly to many Rabmarked cargos [47] [48] [49] [50] [51] . Our data also show that the microtubule-associated form of LRRK2 has its kinase in a closed (and potentially active) conformation. Given this, it is possible that when microtubule-associated LRRK2 stalls the movement of kinesin and dynein, this increases the likelihood that LRRK2 will phosphorylate cargo-associated Rab GTPases on their switch 2 region 8 , ultimately leading to effector dissociation 8 and cargo release. This scenario suggests that increased microtubule binding by LRRK2 carrying PD mutations could (1) block membrane transport driven by molecular motors by acting as a roadblock, (2) lead to increased phosphorylation of physiological microtubuleassociated substrates and/or phosphorylation of non-physiological substrates, or (3) a combination of the first two points. In support of this idea, the four familial PD mutations that enhance LRRK2 microtubule binding 13 also show higher levels of Rab GTPase phosphorylation in cells than the G2019S LRRK2 mutant 8, 9, 52 , whose microtubule binding is not enhanced over wild-type LRRK2 13 . Testing this and other models is an important future direction to understand the cell biological function of both wild-type and pathogenic LRRK2.
Regardless of what role LRRK2's binding to microtubules plays in PD, our data have important implications for the design of LRRK2 kinase inhibitors for therapeutic purposes. Our data predict that treatment with inhibitors that promote binding of LRRK2 to microtubules by favoring a closed conformation of its kinase will block microtubulebased trafficking, while inhibitors that favor an open conformation of the kinase will not.
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